Pemetrexed for the treatment of non-small cell lung cancer. (Q38107552)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Pemetrexed for the treatment of non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Erika Rijavec

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Claudio Sini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Giulia Barletta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Grazia Savarino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Francesco Boccardo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

17 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1545-1558

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pharmacokinetic evaluation of pemetrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by mainte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Management of non-small cell lung in cancer patients with stable disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

Cost‐effectiveness of bevacizumab‐based therapy versus cisplatin plus pemetrexed for the first‐line treatment of advanced non‐squamous NSCLC in Korea and Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774